• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief

N/A
N/A
Protected

Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Copied!
2
0
0

Pełen tekst

(1)

1

The Voice of the Editor-in-Chief

I have decided to start the introduction to the cur- rent issue of “Clinical Diabetology” in more personal and slightly sentimental way. The release of this issue coincides with the 19th Scientific Congress of the Dia- betes Poland (PTD) which is held on May 24–26 2018 in Katowice. Due to its location, this year’s Congress will be of special emotional value for me (which is reflected in the Voice of the Editor-in-Chief), because my entire private and professional life was related to Silesia region. I would like to mention here the person who was my mentor, a precursor of modern diabetology in Silesia, without whom Silesian diabetology would not be where it is now. Felicja Pietraszek passed away two years ago at the age of 92 and unfortunately did not live to see the next PTD Congress in Silesia. She was a great doctor and teacher, but first of all a good man.

She was the founder of the Provincial Diabetes Clinic which is functioning until today. Doctor Pietraszek would certainly enjoy such a wonderful event orga- nized once again in Katowice. With reference to the PTD Congress, it should be mentioned that the Chair of the Organizing Committee is Professor Przemysła- wa Jarosz-Chobot whose knowledge and outstanding personality make me sure that apart from the high scientific level, the Congress will offer the opportunity to attend interesting cultural events.

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who, thanks to the ORKIESTRA Founda- tion, received insulin pump therapy during pregnancy.

Another important multicentre study, the results of which are published in the current issue, is the DIABCON study addressing extremely important, often overlooked, aspect of dealing with a diabetic patient, which is com- pliance with the recommendations for glycemic control.

This issue also contains two review papers that discuss interesting and intriguing topics. The first one refers to the impact of genetic factors; it explains that the expression of specific genes (subject to epigenetic modification under the influence of, e.g., environmental stimuli), may have an effect on the development of diabetes and its com- plications by affecting the phenotype of the organism.

The second article makes the readers wonder whether there is still room for human insulin in contemporary insulin therapy regimens in the aspect of the emergence of newer and faster acting insulin preparations.

As usual, I invite you not only to read, but also to actively contribute to our journals, “Clinical Diabeto- logy” and “Diabetologia Praktyczna”, by submitting interesting manuscripts and comments on the topics discussed by other authors.

Editor-in-Chief

Prof. Janusz Gumprecht

Dear Colleagues,

(2)

Cytaty

Powiązane dokumenty

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with

In addition to attending the scientific meetings, I also encourage you to read the latest issue of the “Clinical Diabetology”, where, among a number of interesting articles, I would